<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806178</url>
  </required_header>
  <id_info>
    <org_study_id>BCG IMMUNO Bladder</org_study_id>
    <nct_id>NCT04806178</nct_id>
  </id_info>
  <brief_title>Immunological Response of Bladder Cancer Patients Under BCG</brief_title>
  <acronym>IMMUNOBCG</acronym>
  <official_title>Systemic Immunological Response of Bladder Cancer Patients Under Bacillus Calmette Guérin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordination for the Improvement of Higher Education Personnel (CAPES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer (BC) is one of the most common cancers worldwide and the most successful&#xD;
      example of vaccine in cancer treatment, representing an efficient model for studying the&#xD;
      importance of systemic and local immune mechanisms. Despite being the standard of treatment&#xD;
      for the last 40 years, the exact mode of action of immunotherapy with the bacillus&#xD;
      Calmette-Guérin (BCG) is still poorly defined. In a mechanistic study, the investigators&#xD;
      intend to prospectively investigate immunological signatures, including immune-checkpoints,&#xD;
      pre and post-treatment in patients with BC, and correlate the cytokines of the immune&#xD;
      by-product and BCG administration pathway to understand the independent contributions of BCG&#xD;
      priming (prior exposure to BCG) and crosstalk immunotherapy between tumor profiles and immune&#xD;
      response of the patient. The proposed research strategy is justified by the need to identify&#xD;
      subsets of patients who better respond to an intervention, or to predict why new&#xD;
      immunotherapies and drugs may be successful or failed in clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recognizing patient-to-patient variability, key data scarcity, and insight into traditional&#xD;
      reductionist therapy, the BCG model offers exceptionally compelling opportunities to&#xD;
      understand how immune system behavior in health and disease emerges from local, systemic,&#xD;
      genetic, epigenetic, cellular, and environmental modulating factors.&#xD;
&#xD;
      The application seeks to change the current clinical practice and research paradigms, by&#xD;
      using new theoretical concepts, challenging bladder cancer patients with a highly effective,&#xD;
      safe, and affordable immunotherapy, the gold standard in the last 40 years of NMIBC, and in&#xD;
      light of new concepts and methodologies brought by the paradigm of immune-checkpoint&#xD;
      inhibitors that justified the Nobel Prize in Physiology or Medicine in 2018.&#xD;
&#xD;
      The current proposal has the potential to impact the prognosis and identification of those&#xD;
      who are unlikely to respond to immune-checkpoint inhibitors, scenarios in which important&#xD;
      unanswered questions remain, particularly as this class of agents advances along the spectrum&#xD;
      of non-metastatic disease.&#xD;
&#xD;
      In a mechanistic approach, patients diagnosed with NMIBC and with the indication for&#xD;
      intravesical BCG treatment will be randomized to placebo versus a priming intradermic BCG 14&#xD;
      days before the intravesical treatment and followed up to 180 days.&#xD;
&#xD;
      The investigators will define important clinical paradigms:&#xD;
&#xD;
        1. The role of the priming effect on the immune system and better understanding of BCG&#xD;
           immunotherapy, with a clear potential for improvement of bladder cancer treatment in&#xD;
           NMIBC and MIBC scenarios;&#xD;
&#xD;
        2. The potential of BCG, a widely used vaccine, to improve or impair the results of new&#xD;
           immunotherapies, given its long-lasting effect;&#xD;
&#xD;
        3. Rational to develop future treatment associations of BCG and immune-checkpoints. \&#xD;
&#xD;
      Under the new immunological concepts, a better understanding of tumor-associated immune&#xD;
      responses in BC patients could provide more informed clinical decisions and treatment&#xD;
      optimization.&#xD;
&#xD;
      Considering the growing need of assessing the value of treatment at the expense of cost, part&#xD;
      of our proposal strategy is to limit financial toxicity as an important issue in cancer&#xD;
      treatment and new immunotherapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Cytometry</measure>
    <time_frame>Day 0</time_frame>
    <description>Cellular Immune Response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Cytometry</measure>
    <time_frame>Day 14</time_frame>
    <description>Cellular Immune Response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Cytometry</measure>
    <time_frame>Day 21</time_frame>
    <description>Cellular Immune Response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Cytometry</measure>
    <time_frame>Day 35</time_frame>
    <description>Cellular Immune Response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Cytometry</measure>
    <time_frame>Day 49</time_frame>
    <description>Cellular Immune Response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Cytometry</measure>
    <time_frame>Day 180</time_frame>
    <description>Cellular Immune Response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects and Change from Baseline Voiding Symptoms</measure>
    <time_frame>Day 21</time_frame>
    <description>American Urological Association Symptom Score Questionnaire - minimum 0 and maximum 35, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects and Change from Baseline Voiding Symptoms</measure>
    <time_frame>Day 35</time_frame>
    <description>American Urological Association Symptom Score Questionnaire - minimum 0 and maximum 35, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects and Change from Baseline Voiding Symptoms</measure>
    <time_frame>Day 49</time_frame>
    <description>American Urological Association Symptom Score Questionnaire - minimum 0 and maximum 35, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Bacillus Calmette-Guerin</condition>
  <arm_group>
    <arm_group_label>BCG intradermal vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intradermal BCG Group (n=16): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group (n = 16): 0.9% saline solution in the same volume as BCG vaccine in a single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bacillus Calmette Guerin</intervention_name>
    <description>0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.</description>
    <arm_group_label>BCG intradermal vaccine</arm_group_label>
    <other_name>BCG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NMIBC with the indication for intravesical BCG treatment;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous BCG treatment;&#xD;
&#xD;
          -  Muscle invasive tumor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo O Reis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana S Dal Col, MD</last_name>
    <phone>+55 19 3521 7481</phone>
    <email>saboya.lu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana S Dal Col</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Ji N, Mukherjee N, Morales EE, Tomasini ME, Hurez V, Curiel TJ, Abate G, Hoft DF, Zhao XR, Gelfond J, Maiti S, Cooper LJN, Svatek RS. Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. Oncoimmunology. 2019 May 25;8(8):1614857. doi: 10.1080/2162402X.2019.1614857. eCollection 2019.</citation>
    <PMID>31413921</PMID>
  </reference>
  <reference>
    <citation>van Puffelen JH, Keating ST, Oosterwijk E, van der Heijden AG, Netea MG, Joosten LAB, Vermeulen SH. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol. 2020 Sep;17(9):513-525. doi: 10.1038/s41585-020-0346-4. Epub 2020 Jul 16. Review.</citation>
    <PMID>32678343</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Leonardo Oliveira Reis</investigator_full_name>
    <investigator_title>Professor Livre Docente</investigator_title>
  </responsible_party>
  <keyword>BCG</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

